Trial Profile

Efficacy, Safety, and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 137173A (Primary)
Indications Herpes zoster; Varicella zoster virus infections
Focus Registrational; Therapeutic Use
Acronyms ZOE-50; ZOSTER-006
Sponsors GlaxoSmithKline; GSK

Most Recent Events

05 Oct 2021 Results of a post hoc analysis published in the Journal of Infectious Diseases
25 Oct 2020 Results assessing vaccine efficacy (VE) of the adjuvanted recombinant zoster vaccine from NCT01165177, NCT01165229 and NCT01610414 presented at the IDWeek 2020.
05 May 2019 this trial is discontinued in france.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com